Diagnostic Values of Galectin-3, Soluble ST2 and BNP in Predicting the Clinical Outcome of ST-Segment Elevation Myocardial Infarction Patients

NCT05246215 | Not Yet Recruiting

• 1 other identifier: DV_Gal_3,sST2
• Study Type: observational
• Target: 90
• Locations: 0 countries
• Sites: N/A

Brief Summary

An acute ST-elevation myocardial infarction occurs due to occlusion of one or more coronary arteries, causing transmural myocardial ischemia which in turn results in myocardial injury or necrosis. Acute myocardial infarction (AMI) may lead to the development of heart failure (HF). Accessible diagnostic tools commonly used in HF such as natriuretic peptides and (NYHA) classification reflect already overt clinical HF. Troponin and creatine kinase reflect myocardial damage, but their usefulness in predicting long-term LVR is limited. Recent guidelines on HF management stressed that HF onset may be delayed or prevented through certain Interventions, such as pharmacotherapy ,post infarction rehabilitation, or modification of HF risk factors. Therefore, it is important to identify potential markers, which would be more informative of HF preclinical stages to recognize patients with an increased risk of HF onset, and to start treatment in advance (1) Gal-3 participates in inflammation and pro fibrotic pathways, while sST2 is a biomarker of inflammation, cardiac mechanical strain, and tissue fibrosis, both of which may predict LVR (2). sST is a biomarker of inflammation, cardiac mechanical strain, and tissue fibrosis(3). B\_type natriuretic peptide (BNP) is elevated in acute myocardial infarction and is a quantitative biochemical marker related to the extent of infarction and left ventricular systolic dysfunction(4).

Conditions

ST Elevation Myocardial Infarction; HF - Heart Failure; Stable Angina

Keywords

Galectin-3

Outcome Measures

Primary Outcomes (1)

• investigate the association of Gal-3, sST2 and BNP concentrations and the development of clinically overt HF in patients after ST-segment elevation myocardial infarction (STEMI) treated with primary percutaneous coronary intervention

  7 months

Study Arms (3)

STEMI group.

60 participants of patients with STEMI treated with primary percutaneous coronary intervention (pPCI).

healthy group.

15 participants of healthy people as a case control.

Stable angina group.

15 participants of patients stable angina

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Assuit University Hospital.

You may qualify if:

• Age ≥ 18 years.
• Hospital admission due to first-time STEMI treated with pPCI.

You may not qualify if:

• History of previous acute coronary syndrome, Previously diagnosed HF or asymptomatic LV dysfunction with LVEF \<50% or previously diagnosed significant valvular disease or any other previously diagnosed structural heart disease Severe renal dysfunction, Severe liver disease, Chronic inflammatory disease, Current neoplastic disease

Sponsors & Collaborators

• Assiut University: lead

MeSH Terms

Conditions

ST Elevation Myocardial Infarction; Heart Failure; Angina, Stable

Condition Hierarchy (Ancestors)

Myocardial Infarction; Myocardial Ischemia; Heart Diseases; Cardiovascular Diseases; Vascular Diseases; Infarction; Ischemia; Pathologic Processes; Pathological Conditions, Signs and Symptoms; Necrosis; Angina Pectoris; Chest Pain; Pain; Neurologic Manifestations; Signs and Symptoms

Central Study Contacts

Aya Khalifa Abdelzaher

CONTACT

+201158166015; aya.khalifa150@hotmail.com

Study Design

• Study Type: observational
• Observational Model: CASE CONTROL
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Resident doctor.

Study Record Dates

• First Submitted: February 9, 2022
• First Posted: February 18, 2022
• Study Start: March 1, 2022
• Primary Completion: December 1, 2025
• Study Completion: March 1, 2026
• Last Updated: February 18, 2022

Record last verified: 2022-02